This segment focuses on the development, commercialization, and application of the Parsortix cell separation system. The Parsortix system is designed to isolate and harvest circulating tumor cells (CTCs) from a patient's blood sample. Research and development activities include continuous improvement of the Parsortix system, development of new assays for different cancer types, and exploration of new applications for CTC analysis. The core technology involves microfluidic devices and cell separation techniques. This segment addresses the need for early and accurate cancer detection, monitoring treatment response, and guiding personalized medicine approaches. The Parsortix system offers a non-invasive method for obtaining valuable information about a patient's cancer, potentially improving patient outcomes by enabling earlier intervention and more effective treatment strategies. Market positioning is strong due to the FDA clearance of the Parsortix system. Future opportunities include expansion into new cancer types, development of companion diagnostics, and integration with other diagnostic technologies. Regulatory and clinical aspects are critical, with ongoing clinical trials and regulatory submissions. Partnerships with pharmaceutical companies and research institutions are key to expanding the application of the Parsortix system.

This segment provides specialist circulating tumor cell (CTC) enrichment and analysis services to support translational research studies and pharmaceutical trials. The R&D activities involve developing and validating new assays, optimizing CTC isolation protocols, and exploring novel biomarkers for cancer detection and monitoring. The technologies and methodologies used include the Parsortix system, downstream analysis tools like HyCEAD, and various molecular biology techniques. This segment supports research in various therapeutic areas, including oncology, with a focus on understanding cancer progression, drug resistance, and treatment response. The impact on patients is indirect, as the research services contribute to the development of new cancer therapies and diagnostic tools. Market positioning is based on providing high-quality CTC analysis services to researchers and pharmaceutical companies. Future opportunities include expanding the range of services offered, developing new analytical capabilities, and partnering with more research institutions and pharmaceutical companies. Regulatory and clinical aspects are relevant, as the research services support clinical trials and contribute to the development of regulated diagnostic products. Partnerships and collaborations with academic institutions and pharmaceutical companies are essential for driving innovation and expanding the reach of the research services.